Related Experiment Videos
Meta-[123I]iodobenzylguanidine single photon emission computed tomography in chemodectomas
G Virotta1, G Medolago, C Zappone
1Division of Nuclear Medicine, Ospedali Riuniti, Bergamo, Italy.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)
|December 1, 1995
Summary
123I-MIBG SPECT is effective for diagnosing untreated chemodectoma (CH). This imaging technique shows promise for monitoring residual disease after surgery and guiding future radiometabolic therapy.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Chemodectoma (CH) is a rare, locally aggressive neoplasm originating from paraganglionic tissue.
- Surgical removal of CH often results in residual disease.
- Metaiodobenzylguanidine (MIBG) uptake is characteristic of paraganglionic-derived tumors.
Purpose of the Study:
- To evaluate the diagnostic accuracy of 123I-MIBG Single Photon Emission Computed Tomography (SPECT) for chemodectoma.
- To compare 123I-MIBG SPECT with Selective Digital Angiography (SDA), Computed Tomography (CT), and Magnetic Resonance Imaging (MRI).
Main Methods:
- 50 patients with suspected chemodectoma underwent 123I-MIBG SPECT, with 26 examined pre-surgery and 24 post-surgery.
- SPECT imaging was performed 4 hours after intravenous administration of 185 MBq of 123I-MIBG.
- Qualitative evaluation of reconstructed SPECT slices was conducted.
Main Results:
- In pre-surgery patients (Group A), 123I-MIBG SPECT accurately identified all 24 chemodectomas, consistent with SDA, CT, and MRI.
- In post-surgery patients (Group B), 123I-MIBG SPECT detected local residuals in 6 patients and was negative in 9.
- Small lesions (<1.5 cm) were often negative on SPECT; three patients had positive SPECT scans without corresponding lesions on conventional imaging.
Conclusions:
- 123I-MIBG SPECT is a valuable tool for diagnosing untreated chemodectoma.
- Post-surgery, 123I-MIBG SPECT can aid in detecting residual disease.
- This imaging modality holds potential for guiding future 131I-MIBG radiometabolic therapy.